Yizun Biotech

Next-generation universal cell therapy drug development company for solid tumors co-founded by Dr. Liu Lingfeng, a prominent expert in the field of immunotherapy from Fred Hutchinson Institute in Seattle. The Company has developed a proprietary duel targeting system and a unique protein degradation technology platform to enable off-the-shelf T-cell therapy featuring NK cell characteristics. Its lead product demonstrated promising safety and efficacy in late-stage liver cancer patients in an IIT study.